Join the IFOPA and Clementia for an Important Webinar

Phase 2 Trial Webinar

We hope you’ll join us Wednesday, Nov. 30, 2016, 11 am to noon Eastern Time, for an important webinar presented by Clementia on the top-line results from the phase 2 trial of palovarotene for treatment of patients with fibrodysplasia ossificans progressiva. 


Dr. Fred Kaplan, The University of Pennsylvania, and Dr. Donna Grogan, Clementia, will lead the webinar. Clinical trial participants were among the first to hear these results and now we are pleased to share them community-wide.

Clementia’s CEO Clarissa Desjardins, PhD shared in a public letter on Oct. 14, “Several positive trends were detected in this 40-subject placebo-controlled trial, including palovarotene-related reductions in the proportion of subjects who developed new HO, reductions in volume of new HO, reductions in patient-reported pain associated with flare-ups, and reductions in the time to resolution of FOP-related flare-ups though none reached statistical significance. Palovarotene was well-tolerated, with all subjects completing the 12-week trial and enrolling into the open-label extension trial. Full results of the phase 2 trial are expected to be published next year. Clementia continues to gather important additional data in the phase 2 extension trial and in the ongoing observational Natural History Study. Data from these studies will inform the design of a phase 3 registration trial, which is expected to start in 2017.”

The webinar is open to anyone interested in FOP research and drug development. Registration is now closed. 


To learn more about Clementia studies and trials that are currently recruiting, please visit the following links:

An Open-Label Extension Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter